JP2020183387A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020183387A5 JP2020183387A5 JP2020107507A JP2020107507A JP2020183387A5 JP 2020183387 A5 JP2020183387 A5 JP 2020183387A5 JP 2020107507 A JP2020107507 A JP 2020107507A JP 2020107507 A JP2020107507 A JP 2020107507A JP 2020183387 A5 JP2020183387 A5 JP 2020183387A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- preparation according
- antibody concentration
- aqueous pharmaceutical
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 3
- 229960002964 adalimumab Drugs 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US499207P | 2007-11-30 | 2007-11-30 | |
| US61/004,992 | 2007-11-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015112856A Division JP6752500B2 (ja) | 2007-11-30 | 2015-06-03 | タンパク質製剤及びその製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020183387A JP2020183387A (ja) | 2020-11-12 |
| JP2020183387A5 true JP2020183387A5 (2) | 2021-03-25 |
Family
ID=40718465
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010536208A Active JP5840364B2 (ja) | 2007-11-30 | 2008-11-28 | タンパク質製剤及びその製造方法 |
| JP2014075367A Pending JP2014159437A (ja) | 2007-11-30 | 2014-04-01 | タンパク質製剤及びその製造方法 |
| JP2015112856A Active JP6752500B2 (ja) | 2007-11-30 | 2015-06-03 | タンパク質製剤及びその製造方法 |
| JP2016107020A Pending JP2016185971A (ja) | 2007-11-30 | 2016-05-30 | タンパク質製剤及びその製造方法 |
| JP2018008763A Pending JP2018080202A (ja) | 2007-11-30 | 2018-01-23 | タンパク質製剤及びその製造方法 |
| JP2020107507A Pending JP2020183387A (ja) | 2007-11-30 | 2020-06-23 | タンパク質製剤及びその製造方法 |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010536208A Active JP5840364B2 (ja) | 2007-11-30 | 2008-11-28 | タンパク質製剤及びその製造方法 |
| JP2014075367A Pending JP2014159437A (ja) | 2007-11-30 | 2014-04-01 | タンパク質製剤及びその製造方法 |
| JP2015112856A Active JP6752500B2 (ja) | 2007-11-30 | 2015-06-03 | タンパク質製剤及びその製造方法 |
| JP2016107020A Pending JP2016185971A (ja) | 2007-11-30 | 2016-05-30 | タンパク質製剤及びその製造方法 |
| JP2018008763A Pending JP2018080202A (ja) | 2007-11-30 | 2018-01-23 | タンパク質製剤及びその製造方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8420081B2 (2) |
| EP (2) | EP2231175A4 (2) |
| JP (6) | JP5840364B2 (2) |
| KR (4) | KR20190045414A (2) |
| CN (3) | CN104740632A (2) |
| AU (1) | AU2008334099B2 (2) |
| BR (1) | BRPI0819714A8 (2) |
| CA (2) | CA2707483A1 (2) |
| IL (4) | IL206081A (2) |
| MX (1) | MX354100B (2) |
| NZ (4) | NZ602498A (2) |
| RU (2) | RU2473360C2 (2) |
| SG (2) | SG186607A1 (2) |
| TW (4) | TW200938221A (2) |
| WO (1) | WO2009073569A2 (2) |
| ZA (1) | ZA201205433B (2) |
Families Citing this family (181)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| MX336813B (es) * | 1996-02-09 | 2016-02-02 | Abbvie Biotechnology Ltd | Anticuerpos humanos que ligan el tnfa humano. |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
| WO2004009776A2 (en) * | 2002-07-19 | 2004-01-29 | Abbott Biotechnology Ltd. | TREATMENT OF TNFα RELATED DISORDERS |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| MY150740A (en) * | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| TW201705980A (zh) * | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
| WO2006041970A2 (en) * | 2004-10-08 | 2006-04-20 | Abbott Biotechnology Ltd. | Treatment of respiratory syncytial virus (rsv) infection |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| NZ595225A (en) | 2005-05-16 | 2013-05-31 | Abbott Biotech Ltd | Use of tnf inhibitor for treatment of erosive polyarthritis |
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| CN103336129A (zh) * | 2005-11-01 | 2013-10-02 | 阿布维生物技术有限公司 | 使用生物标志物诊断强直性脊柱炎的方法和组合物 |
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| CN102887955A (zh) | 2006-04-05 | 2013-01-23 | 艾博特生物技术有限公司 | 抗体纯化 |
| WO2007120626A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
| US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
| WO2008063213A2 (en) | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
| US9399061B2 (en) * | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| US9605064B2 (en) * | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| US20080311043A1 (en) * | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| MX2008016335A (es) | 2006-06-30 | 2009-01-21 | Abbott Biotech Ltd | Dispositivo automatico de inyeccion. |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| AU2007294731B2 (en) | 2006-09-13 | 2014-04-17 | Abbvie Inc. | Cell culture improvements |
| ES2442258T3 (es) | 2006-10-27 | 2014-02-10 | Abbvie Biotechnology Ltd | Anticuerpos cristalinos anti-hTNF alfa |
| AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| RU2476442C2 (ru) | 2007-03-29 | 2013-02-27 | Эббот Лэборетриз | Кристаллические антитела против il-12 человека |
| WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
| US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
| WO2009008595A1 (en) | 2007-07-10 | 2009-01-15 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
| JP2010533181A (ja) * | 2007-07-13 | 2010-10-21 | アボツト・バイオテクノロジー・リミテツド | ＴＮＦα阻害剤の肺投与のための方法及び組成物 |
| JP5323832B2 (ja) | 2007-08-07 | 2013-10-23 | アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー | 酸性水溶液中にｇｄｆ−５を含むタンパク質製剤 |
| WO2009020654A1 (en) | 2007-08-08 | 2009-02-12 | Abbott Laboratories | Compositions and methods for crystallizing antibodies |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| US20090271164A1 (en) * | 2008-01-03 | 2009-10-29 | Peng Joanna Z | Predicting long-term efficacy of a compound in the treatment of psoriasis |
| CA2711984A1 (en) | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co. Kg | Powdered protein compositions and methods of making same |
| BRPI0911048A2 (pt) | 2008-04-14 | 2015-12-29 | Atrm Llc | formulações líquidas tamponadas de gdf-5 |
| BRPI0920572A8 (pt) | 2008-10-20 | 2015-10-27 | Abbott Lab | Inativação viral durante a purificação dos anticorpos |
| NZ592095A (en) | 2008-10-20 | 2013-01-25 | Abbott Lab | Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography |
| WO2010127146A1 (en) | 2009-04-29 | 2010-11-04 | Abbott Biotechnology Ltd | Automatic injection device |
| US20130034534A1 (en) * | 2009-09-29 | 2013-02-07 | Philipp Kroneberg | Method for treatment of patients with cystic fibrosis |
| CN102574912B (zh) | 2009-09-29 | 2014-12-24 | 弗·哈夫曼-拉罗切有限公司 | 缓冲溶质的过滤前调节 |
| RU2582401C2 (ru) | 2009-12-15 | 2016-04-27 | Эббви Байотекнолоджи Лтд | Усовершенствованная пусковая кнопка для автоматического инъекционного устройства |
| JP2013518590A (ja) | 2010-02-02 | 2013-05-23 | アボツト・バイオテクノロジー・リミテツド | ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物 |
| EP2575884B1 (en) | 2010-06-03 | 2018-07-18 | AbbVie Biotechnology Ltd | Uses and compositions for treatment of hidradenitis suppurativa (hs) |
| JP6073783B2 (ja) | 2010-06-25 | 2017-02-01 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物 |
| LT2588130T (lt) | 2010-06-25 | 2016-12-12 | Shire Human Genetic Therapies, Inc. | Terapinės priemonės pristatymas cns |
| PT3103469T (pt) | 2010-06-25 | 2021-03-04 | Shire Human Genetic Therapies | Administração de agentes terapêuticos no snc |
| KR20230159646A (ko) | 2010-06-25 | 2023-11-21 | 샤이어 휴먼 지네틱 테라피즈 인크. | 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들 |
| HRP20191923T1 (hr) | 2010-06-25 | 2020-01-10 | Shire Human Genetic Therapies, Inc. | Postupci i sastavi za isporuku arilsulfataze a u cns |
| AR082319A1 (es) * | 2010-07-22 | 2012-11-28 | Biomarin Pharm Inc | Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos |
| MX2019000046A (es) | 2010-11-04 | 2023-10-05 | Boehringer Ingelheim Int | Anticuerpos anti-il-23. |
| US8821865B2 (en) * | 2010-11-11 | 2014-09-02 | Abbvie Biotechnology Ltd. | High concentration anti-TNFα antibody liquid formulations |
| CN106822883A (zh) * | 2010-12-14 | 2017-06-13 | 葛兰素史密丝克莱恩生物有限公司 | 分枝杆菌抗原组合物 |
| RU2727040C2 (ru) | 2011-01-24 | 2020-07-17 | Эббви Байотекнолоджи Лтд. | Автоматические инъекционные устройства, имеющие наформованные поверхности захвата |
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| CN103930124B (zh) * | 2011-07-01 | 2021-05-11 | 生物基因Ma公司 | 无精氨酸的tnfr：fc-融合多肽组合物及使用方法 |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| EP2758780A4 (en) * | 2011-09-22 | 2015-09-16 | Marv Entpr Llc | METHOD OF TREATING MULTIPLE SCLEROSIS |
| US10485869B2 (en) | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| BR112014009146A8 (pt) | 2011-10-18 | 2017-06-20 | Coherus Biosciences Inc | formulações de etanercepte estabilizadas com aminoácidos |
| WO2013063277A1 (en) | 2011-10-25 | 2013-05-02 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US20140377244A1 (en) | 2011-12-23 | 2014-12-25 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| WO2013096835A1 (en) * | 2011-12-23 | 2013-06-27 | Abbvie Inc. | Stable protein formulations |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
| PL3326649T3 (pl) | 2012-05-03 | 2022-04-25 | Boehringer Ingelheim International Gmbh | Przeciwciała anty-il-23p19 |
| WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
| WO2013186230A1 (en) * | 2012-06-12 | 2013-12-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation for a therapeutic antibody |
| HK1209343A1 (en) | 2012-07-09 | 2016-04-01 | Coherus Biosciences, Inc. | Etanercept formulations exhibiting marked reduction in sub-visible particles |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| HK1211981A1 (en) | 2012-09-02 | 2016-06-03 | Abbvie Inc. | Methods to control protein heterogeneity |
| PE20150964A1 (es) | 2012-09-07 | 2015-07-25 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab |
| SI2895188T1 (en) | 2012-09-11 | 2018-05-31 | Coherus Biosciences, Inc. | CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE |
| US9844594B2 (en) | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| HK1207960A1 (en) | 2013-03-12 | 2016-02-19 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
| CA2899449A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | Low acidic species compositions and methods for producing the same using displacement chromatography |
| BR112015017307A2 (pt) | 2013-03-14 | 2017-11-21 | Abbvie Inc | composições de espécies com baixa acidez e métodos para produção e uso das mesmas |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| US9017687B1 (en) * | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| RS58351B1 (sr) | 2013-03-15 | 2019-03-29 | Shire Viropharma Inc | C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze |
| US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9717649B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9707153B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9707155B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9839579B2 (en) | 2013-04-24 | 2017-12-12 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9603775B2 (en) | 2013-04-24 | 2017-03-28 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9713572B2 (en) | 2013-04-24 | 2017-07-25 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9717648B2 (en) * | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US9700486B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| EP3057616B1 (en) | 2013-10-16 | 2020-03-11 | Outlook Therapeutics, Inc. | Buffer formulations for enhanced antibody stability |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| CN104707146B (zh) * | 2013-12-16 | 2019-04-16 | 浙江海正药业股份有限公司 | 一种含有阿达木单抗的药物组合物 |
| US10548951B2 (en) | 2013-12-17 | 2020-02-04 | Mhs Care-Innovation Llc | Compositions and methods for treating obesity and hyperphagia |
| RU2711478C2 (ru) | 2013-12-17 | 2020-01-17 | ЭмЭйчЭс КЕА-ИННОВЕЙШН ЭлЭлСи | Композиции и способы борьбы с накоплением жировой ткани |
| WO2015151115A1 (en) | 2014-04-02 | 2015-10-08 | Intas Pharmaceuticals Limited | Liquid pharmaceutical composition of adalimumab |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| PT2946765T (pt) | 2014-05-23 | 2016-11-10 | Ares Trading Sa | Composição farmacêutica líquida |
| EP2946767B1 (en) * | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US11357857B2 (en) * | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| WO2016004197A1 (en) | 2014-07-03 | 2016-01-07 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt |
| WO2016007764A1 (en) | 2014-07-09 | 2016-01-14 | Abbvie Inc. | Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars |
| RU2696312C2 (ru) | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| EP3708679A1 (en) | 2014-07-24 | 2020-09-16 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| EA202193002A2 (ru) | 2014-09-03 | 2022-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединение, нацеленное на ил-23a и фно-альфа, и его применение |
| WO2016065181A1 (en) | 2014-10-23 | 2016-04-28 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| WO2016089946A1 (en) * | 2014-12-02 | 2016-06-09 | Biogen Ma Inc. | Methods and compositions for controlling antibody aggregation |
| WO2016118707A1 (en) | 2015-01-21 | 2016-07-28 | Oncobiologics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| MX2017009759A (es) | 2015-01-28 | 2017-10-27 | Pfizer | Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable. |
| AU2016215535B2 (en) | 2015-02-04 | 2021-09-16 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
| EP4523756A3 (en) | 2015-02-13 | 2025-05-28 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| EP3078675A1 (en) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induction dosing regimen for the treatment of tnf alpha mediated disorders |
| CA3002373A1 (en) * | 2015-10-23 | 2017-04-27 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| CN109563161A (zh) | 2016-02-03 | 2019-04-02 | 安口生物公司 | 用于提高抗体稳定性的缓冲制剂 |
| GB201603280D0 (en) | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
| EP3439701A4 (en) | 2016-04-08 | 2019-12-11 | 180 Therapeutics LP | METHOD FOR THE TREATMENT OF DUPUYTRIAL DISEASE IN EARLY STAGE |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| WO2018033482A1 (en) * | 2016-08-17 | 2018-02-22 | Boehringer Ingelheim International Gmbh | Process for the preparation of highly concentrated liquid formulations containing biomolecules |
| CN107773755B (zh) * | 2016-08-31 | 2021-06-22 | 上海津曼特生物科技有限公司 | 抗表皮生长因子受体单克隆抗体的注射液制剂 |
| KR102480965B1 (ko) | 2016-09-13 | 2022-12-26 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
| CN110177805B (zh) | 2016-10-19 | 2024-04-02 | 英温拉公司 | 抗体构建体 |
| PT3528787T (pt) | 2016-10-21 | 2026-03-11 | Amgen Inc | Formulações farmacêuticas e métodos para produzir as mesmas |
| MX2019005833A (es) | 2016-11-21 | 2019-10-30 | Eirion Therapeutics Inc | Administracion transdermica de agentes grandes. |
| EP3541413A2 (en) | 2016-11-21 | 2019-09-25 | Polpharma Biologics S.A. | Aqueous pharmaceutical formulations |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| AU2017383142A1 (en) | 2016-12-22 | 2019-07-04 | Università Degli Studi Magna Graecia Catanzaro | A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of CD43 |
| AU2017386888B2 (en) | 2016-12-28 | 2024-08-08 | Jcr Pharmaceuticals Co., Ltd. | Lyophilized preparation |
| RU2665966C2 (ru) * | 2016-12-30 | 2018-09-05 | Закрытое Акционерное Общество "Биокад" | Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα |
| JP6172880B1 (ja) * | 2017-02-01 | 2017-08-02 | 協和発酵キリン株式会社 | ダルベポエチンを含む液体医薬組成物 |
| JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| US10799597B2 (en) | 2017-04-03 | 2020-10-13 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| CN110769848A (zh) * | 2017-05-16 | 2020-02-07 | 瑞士奥克特珐玛公司 | C1-酯酶抑制剂制剂 |
| JP7820910B2 (ja) | 2017-09-20 | 2026-02-26 | アルヴォテック エイチエフ | アダリムマブ用医薬製剤 |
| EP3459527B1 (en) * | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization |
| RU2020121415A (ru) * | 2017-11-30 | 2021-12-30 | Био-Тера Солюшнз, Лтд. | Жидкий препарат гуманизированного антитела для лечения заболеваний, опосредованных ил-6 |
| GB201721846D0 (en) * | 2017-12-22 | 2018-02-07 | Arecor Ltd | Novel composition |
| WO2019147824A1 (en) | 2018-01-26 | 2019-08-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| MX2020010724A (es) * | 2018-04-12 | 2020-11-06 | Amgen Inc | Metodos para preparar composiciones proteicas estables. |
| CN120795120A (zh) | 2018-06-05 | 2025-10-17 | 伦敦大学国王学院 | 向胃肠系统递送酬载的btnl3/8导引构建体 |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US20230033021A1 (en) | 2018-06-20 | 2023-02-02 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| US20210363233A1 (en) | 2018-06-20 | 2021-11-25 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| WO2019246273A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| US20230312700A1 (en) | 2018-06-20 | 2023-10-05 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
| MY195550A (en) | 2018-10-29 | 2023-01-31 | Hoffmann La Roche | Antibody Formulation |
| CN111228225B (zh) * | 2018-11-28 | 2022-08-26 | 鲁南制药集团股份有限公司 | 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂 |
| US20220080023A1 (en) | 2018-12-21 | 2022-03-17 | Arecor Limited | Novel composition |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| AU2020279395B2 (en) | 2019-05-22 | 2025-08-28 | Biovie Inc. | Formulations of terlipressin |
| US11684655B2 (en) | 2019-05-31 | 2023-06-27 | Spectrum Pharmaceuticals, Inc. | Methods of treating neutorpenia using G-CSF protein complex |
| US11267858B2 (en) | 2019-05-31 | 2022-03-08 | Spectrum Pharmaceuticals, Inc. | Methods of treatment using G-CSF protein complex |
| GB201911461D0 (en) | 2019-08-09 | 2019-09-25 | Arecor Ltd | Novel composition |
| CN110467273B (zh) * | 2019-08-27 | 2021-08-24 | 暨南大学 | 一种垃圾渗滤液浓缩液的微生物毒性及可生化性评价方法及其应用 |
| TW202535466A (zh) | 2019-09-09 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| KR102414997B1 (ko) * | 2020-09-29 | 2022-06-29 | 주식회사 엘지생활건강 | 안정성이 개선된 재조합 보툴리눔 독소 경쇄 단백질 조성물 |
| KR102375269B1 (ko) * | 2021-01-27 | 2022-03-17 | 한미약품 주식회사 | 단백질 액상 제제 및 이의 제조방법 |
| US20240166718A1 (en) | 2021-02-17 | 2024-05-23 | Arecor Limited | Aqueous composition of an engineered protein construct comprising an fc domain |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| JP2024527538A (ja) * | 2021-07-01 | 2024-07-25 | アップカラ インコーポレイテッド | 生物活性剤の超濃縮製剤 |
| AU2023300419A1 (en) | 2022-07-01 | 2025-01-02 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
| CH720224B1 (de) * | 2023-08-18 | 2024-05-31 | Csl Behring Ag | Verfahren zur Sterilfiltration albuminhaltiger wässriger Lösungen |
Family Cites Families (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US5702699A (en) * | 1982-09-23 | 1997-12-30 | Cetus Corporation | Process for the recovery of lipophilic proteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4597966A (en) * | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4877608A (en) * | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| JP3443119B2 (ja) | 1989-08-07 | 2003-09-02 | ペプテック リミテッド | 腫瘍壊死因子結合リガンド |
| GB9017002D0 (en) * | 1990-08-02 | 1990-09-19 | Health Lab Service Board | Improved method for the purification of erwina l-asparaginase |
| US5469750A (en) | 1991-03-05 | 1995-11-28 | Aradigm Corporation | Method and apparatus for sensing flow in two directions and automatic calibration thereof |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US20060246073A1 (en) * | 1991-03-18 | 2006-11-02 | Knight David M | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| US5694919A (en) | 1993-01-29 | 1997-12-09 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activated dispenser |
| US5507277A (en) | 1993-01-29 | 1996-04-16 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activateddispenser |
| US5888477A (en) | 1993-01-29 | 1999-03-30 | Aradigm Corporation | Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin |
| DK0682710T3 (da) | 1993-02-10 | 2004-03-01 | Unilever Nv | Isolationsmetode, ved hvilken der anvendes immobiliserede proteiner med specifikke kapaciteter |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| DE4344824C1 (de) * | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
| US5509404A (en) | 1994-07-11 | 1996-04-23 | Aradigm Corporation | Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values |
| US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| MX336813B (es) | 1996-02-09 | 2016-02-02 | Abbvie Biotechnology Ltd | Anticuerpos humanos que ligan el tnfa humano. |
| US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6696251B1 (en) | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| ATE332368T1 (de) | 1997-01-21 | 2006-07-15 | Gen Hospital Corp | Selektion von proteinen mittels rns-protein fusionen |
| GB9705810D0 (en) * | 1997-03-20 | 1997-05-07 | Common Services Agency | Intravenous immune globulin |
| EP0975748B1 (en) | 1997-04-23 | 2006-03-29 | Universität Zürich | Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules |
| CZ298429B6 (cs) * | 1997-04-28 | 2007-10-03 | Eli Lilly And Company | Stabilní lyofilizovaný prostredek |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US5886154A (en) * | 1997-06-20 | 1999-03-23 | Lebing; Wytold R. | Chromatographic method for high yield purification and viral inactivation of antibodies |
| JPH1129294A (ja) * | 1997-07-09 | 1999-02-02 | Tochigi Fuji Ind Co Ltd | ウインチ |
| US5855564A (en) | 1997-08-20 | 1999-01-05 | Aradigm Corporation | Aerosol extrusion mechanism |
| CA2323638A1 (en) | 1998-04-03 | 1999-10-14 | Phylos, Inc. | Addressable protein arrays |
| DK2270044T3 (en) * | 1998-06-09 | 2015-01-26 | Csl Behring Ag | Liquid immunoglobulin G (IgG) product |
| US6846655B1 (en) | 1998-06-29 | 2005-01-25 | Phylos, Inc. | Methods for generating highly diverse libraries |
| JP2002522091A (ja) | 1998-08-17 | 2002-07-23 | フィロス インク． | ３’非翻訳領域を欠損する核酸を生成して細胞ｒｎａ蛋白質融合体形成を最適化する方法 |
| JP4278872B2 (ja) | 1998-08-17 | 2009-06-17 | フィロス インク． | 蛋白質・核酸融合分子ライブラリーを用いた化合物・蛋白質相互作用の同定 |
| NZ511699A (en) | 1998-12-02 | 2003-02-28 | Phylos Inc | DNA-protein fusions and uses thereof |
| DK1144616T4 (da) | 1999-01-19 | 2009-03-30 | Unilever Nv | Fremgangsmåde til fremstilling af antistoffragmenter |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| CA2371427A1 (en) | 1999-04-28 | 2000-11-09 | Yamanouchi Pharmaceutical Co., Ltd. | Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof |
| US6623926B1 (en) | 1999-06-01 | 2003-09-23 | Phylos, Inc. | Methods for producing 5′-nucleic acid-protein conjugates |
| AU778194B2 (en) | 1999-07-12 | 2004-11-18 | Bristol-Myers Squibb Company | C-terminal protein tagging |
| DK1196637T3 (da) | 1999-07-27 | 2007-07-30 | Adnexus Therapeutics Inc | Peptidacceptor-ligeringsmetoder |
| US6436665B1 (en) | 1999-08-27 | 2002-08-20 | Phylos, Inc | Methods for encoding and sorting in vitro translated proteins |
| US7022479B2 (en) | 2000-01-24 | 2006-04-04 | Compound Therapeutics, Inc. | Sensitive, multiplexed diagnostic assays for protein analysis |
| DE60118527D1 (de) | 2000-01-24 | 2006-05-18 | Compound Therapeutics Inc | Sensible und multiplexe diagnostische tests zur proteinanalyse |
| DE10013093B4 (de) | 2000-03-17 | 2005-12-22 | Inamed Gmbh | Vorrichtung zur kontrollierten Inhalation therapeutischer Aerosole |
| JP5490972B2 (ja) * | 2000-08-04 | 2014-05-14 | 中外製薬株式会社 | タンパク質注射製剤 |
| UA81743C2 (uk) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| JP5485489B2 (ja) * | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| US6693173B2 (en) * | 2000-12-26 | 2004-02-17 | Alpha Therapeutic Corporation | Method to remove citrate and aluminum from proteins |
| DE10123749A1 (de) | 2001-05-16 | 2002-12-12 | Inamed Gmbh | Vorrichtung zum Verabreichen von Aerosolen |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| US20030012786A1 (en) | 2001-05-25 | 2003-01-16 | Teoh Leah S. | Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| AU2002310502A1 (en) | 2001-06-21 | 2003-01-08 | Phylos, Inc. | In vitro protein interaction detection systems |
| AU2002365404A1 (en) | 2001-11-27 | 2003-06-10 | Compound Therapeutics, Inc. | Solid-phase immobilization of proteins and peptides |
| US20030143603A1 (en) * | 2001-11-30 | 2003-07-31 | Jill Giles-Komar | Anti-TNF antibodies, compositions, methods and uses |
| GB0202633D0 (en) * | 2002-02-05 | 2002-03-20 | Delta Biotechnology Ltd | Stabilization of protein preparations |
| CN101721362B (zh) * | 2002-02-14 | 2018-07-03 | 中外制药株式会社 | 包含抗体的溶液制剂 |
| US20030161828A1 (en) | 2002-02-19 | 2003-08-28 | Abbott Gmbh & Co. Kg | Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure |
| SI1478394T1 (sl) * | 2002-02-27 | 2008-12-31 | Immunex Corp | STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM |
| US20040105889A1 (en) * | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
| US20040009172A1 (en) | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| CN1671741A (zh) * | 2002-06-21 | 2005-09-21 | 拜奥根Idec公司 | 浓缩抗体的缓冲剂制剂及其使用方法 |
| WO2004004798A2 (en) * | 2002-07-03 | 2004-01-15 | The Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
| US20090280065A1 (en) | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
| WO2004009776A2 (en) | 2002-07-19 | 2004-01-29 | Abbott Biotechnology Ltd. | TREATMENT OF TNFα RELATED DISORDERS |
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| EP3225625A1 (en) * | 2002-09-11 | 2017-10-04 | Chugai Seiyaku Kabushiki Kaisha | Protein purification method |
| MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| JP4500683B2 (ja) * | 2002-11-01 | 2010-07-14 | バイエル・ヘルスケア・エルエルシー | 巨大分子濃縮方法 |
| US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
| KR101235507B1 (ko) * | 2003-02-28 | 2013-02-20 | 추가이 세이야쿠 가부시키가이샤 | 단백질을 함유하는 안정화 제제 |
| JP4980048B2 (ja) * | 2003-02-28 | 2012-07-18 | アレス トレーディング ソシエテ アノニム | 腫瘍壊死因子結合タンパク質の液体製剤 |
| MXPA05010555A (es) * | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| FR2853551B1 (fr) * | 2003-04-09 | 2006-08-04 | Lab Francais Du Fractionnement | Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee |
| US7456147B2 (en) * | 2003-05-14 | 2008-11-25 | Dow Corning, Corporation | Controlled release of active agents utilizing repeat sequence protein polymers |
| RU2364609C2 (ru) * | 2003-05-23 | 2009-08-20 | Ново Нордиск Хелт Кэр Аг | Стабилизация белка в растворе |
| DE602004017726D1 (de) * | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylierte Single-domain-antikörper (dAb) |
| HUE026793T2 (en) * | 2003-10-01 | 2016-07-28 | Kyowa Hakko Kirin Co Ltd | A method for stabilizing an antibody and a stabilized solution-type antibody preparation |
| EP1532983A1 (en) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| EP1712240B1 (en) * | 2003-12-25 | 2015-09-09 | Kyowa Hakko Kirin Co., Ltd. | Stable water-based medicinal preparation containing antibody |
| WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| RU2390353C2 (ru) * | 2004-02-12 | 2010-05-27 | Мерк Патент Гмбх | Высококонцентрированные жидкие композиции анти-egfr антител |
| CA2561845C (en) | 2004-04-02 | 2014-03-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Aerosol delivery systems and methods |
| TW201705980A (zh) | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| AU2005249360B2 (en) * | 2004-04-12 | 2011-07-21 | Medimmune, Llc | Anti-IL-9 antibody formulations and uses thereof |
| MXPA06012992A (es) * | 2004-05-12 | 2007-02-12 | Baxter Int | Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente. |
| TW200621282A (en) * | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| WO2006022599A1 (en) * | 2004-08-27 | 2006-03-02 | Marian Metke | Production method for exfoliated graphite, equipment for its production, exfoliated graphite and means of its use |
| US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| WO2006041970A2 (en) | 2004-10-08 | 2006-04-20 | Abbott Biotechnology Ltd. | Treatment of respiratory syncytial virus (rsv) infection |
| WO2007011390A2 (en) * | 2004-10-09 | 2007-01-25 | Government Of The United States As Represented By The Secretary Of The Army | Large-scale production of human serum butyrylcholinesterase as a bioscavenger |
| WO2006064373A2 (en) * | 2004-12-16 | 2006-06-22 | Genzyme Polyclonals S.A.S. | Methods of purifying immunologlobulins |
| PA8661401A1 (es) * | 2005-01-28 | 2006-09-08 | Wyeth Corp | Formulaciones del liquido polipeptido estabilizado |
| CA2606270A1 (en) * | 2005-04-19 | 2006-10-26 | Massachusetts Institute Of Technology | Amphiphilic polymers and methods of use thereof |
| NZ595225A (en) | 2005-05-16 | 2013-05-31 | Abbott Biotech Ltd | Use of tnf inhibitor for treatment of erosive polyarthritis |
| BRPI0611901A2 (pt) * | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| US20060286108A1 (en) * | 2005-06-16 | 2006-12-21 | Bell Katherine A | Topical compositions for the treatment of chronic wounds |
| DE602006020568D1 (de) * | 2005-07-02 | 2011-04-21 | Arecor Ltd | Stabile wässrige systeme mit proteinen |
| WO2007016562A2 (en) * | 2005-07-29 | 2007-02-08 | Amgen Inc. | Formulations that inhibit protein aggregation |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| RU2422035C2 (ru) * | 2005-09-21 | 2011-06-27 | Баркон Ньютрасайнс (Мб) Корп. | Способ получения белкового изолята канолы, включающий изоэлектрическое осаждение |
| CN103336129A (zh) | 2005-11-01 | 2013-10-02 | 阿布维生物技术有限公司 | 使用生物标志物诊断强直性脊柱炎的方法和组合物 |
| US8337814B2 (en) * | 2005-12-15 | 2012-12-25 | Topical Sinus Therapeutics, Inc. | Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions |
| BRPI0620316A2 (pt) * | 2005-12-21 | 2011-11-08 | Wyeth Corp | formulações de proteìnas com viscosidades reduzida e seus usos |
| US20070202051A1 (en) * | 2006-02-10 | 2007-08-30 | Pari Gmbh | Aerosols for sinunasal drug delivery |
| CN102887955A (zh) | 2006-04-05 | 2013-01-23 | 艾博特生物技术有限公司 | 抗体纯化 |
| US20090317399A1 (en) | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
| US9605064B2 (en) * | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| WO2007120626A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
| US20080118496A1 (en) | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| WO2008063213A2 (en) | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
| US20080131374A1 (en) | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| US20080311043A1 (en) | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| MX2008016335A (es) * | 2006-06-30 | 2009-01-21 | Abbott Biotech Ltd | Dispositivo automatico de inyeccion. |
| AU2007294731B2 (en) | 2006-09-13 | 2014-04-17 | Abbvie Inc. | Cell culture improvements |
| US20100129379A1 (en) * | 2006-09-25 | 2010-05-27 | John Carpenter | Stabilized antibody formulations and uses thereof |
| ES2442258T3 (es) | 2006-10-27 | 2014-02-10 | Abbvie Biotechnology Ltd | Anticuerpos cristalinos anti-hTNF alfa |
| BRPI0720125A2 (pt) * | 2006-12-06 | 2014-01-28 | Wyeth Corp | Método para armazenar uma formulação líquida; método para a preparação de uma formulação líquida; composição; e método para inibir a agregação induzida por manitol de uma proteína em uma formulação líquida. |
| CA2675602A1 (en) * | 2007-02-16 | 2008-08-21 | Wyeth | Protein formulations containing sorbitol |
| WO2008150491A2 (en) | 2007-05-31 | 2008-12-11 | Abbott Laboratories | BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS |
| EP2152318A4 (en) | 2007-06-01 | 2011-12-07 | Abbott Biotech Ltd | COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE |
| WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
| JP2010533181A (ja) | 2007-07-13 | 2010-10-21 | アボツト・バイオテクノロジー・リミテツド | ＴＮＦα阻害剤の肺投与のための方法及び組成物 |
| JP5399389B2 (ja) * | 2007-08-06 | 2014-01-29 | テレフオンアクチーボラゲット エル エム エリクソン（パブル） | Ｌｔｅシステムにおけるｏｆｄｍａアップリンクの干渉による影響の回復 |
| WO2009020654A1 (en) | 2007-08-08 | 2009-02-12 | Abbott Laboratories | Compositions and methods for crystallizing antibodies |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| US20090271164A1 (en) | 2008-01-03 | 2009-10-29 | Peng Joanna Z | Predicting long-term efficacy of a compound in the treatment of psoriasis |
| CA2711984A1 (en) | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co. Kg | Powdered protein compositions and methods of making same |
| TWI478937B (zh) | 2008-01-15 | 2015-04-01 | Abbvie Inc | 改良之哺乳動物表現載體及其用途 |
| JP2011517672A (ja) | 2008-03-24 | 2011-06-16 | アボツト・バイオテクノロジー・リミテツド | 骨損失を治療するための方法及び組成物 |
| JP2012511531A (ja) * | 2008-12-09 | 2012-05-24 | エフ．ホフマン−ラ ロシュ アーゲー | 賦形剤不含抗体溶液を得るための方法 |
| WO2010127146A1 (en) * | 2009-04-29 | 2010-11-04 | Abbott Biotechnology Ltd | Automatic injection device |
| US20100278822A1 (en) * | 2009-05-04 | 2010-11-04 | Abbott Biotechnology, Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| JP2013518590A (ja) * | 2010-02-02 | 2013-05-23 | アボツト・バイオテクノロジー・リミテツド | ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物 |
| EP2575884B1 (en) * | 2010-06-03 | 2018-07-18 | AbbVie Biotechnology Ltd | Uses and compositions for treatment of hidradenitis suppurativa (hs) |
-
2008
- 2008-11-28 US US12/325,049 patent/US8420081B2/en active Active
- 2008-11-28 CN CN201510111453.6A patent/CN104740632A/zh active Pending
- 2008-11-28 WO PCT/US2008/085066 patent/WO2009073569A2/en not_active Ceased
- 2008-11-28 TW TW097146498A patent/TW200938221A/zh unknown
- 2008-11-28 NZ NZ602498A patent/NZ602498A/en unknown
- 2008-11-28 EP EP08857510.5A patent/EP2231175A4/en not_active Withdrawn
- 2008-11-28 CN CN2008801254027A patent/CN101969971A/zh active Pending
- 2008-11-28 TW TW104140979A patent/TWI543768B/zh not_active IP Right Cessation
- 2008-11-28 TW TW107115487A patent/TWI661833B/zh not_active IP Right Cessation
- 2008-11-28 CA CA2707483A patent/CA2707483A1/en not_active Abandoned
- 2008-11-28 BR BRPI0819714A patent/BRPI0819714A8/pt active Search and Examination
- 2008-11-28 MX MX2010005919A patent/MX354100B/es active IP Right Grant
- 2008-11-28 CN CN201510111763.8A patent/CN104645329A/zh active Pending
- 2008-11-28 SG SG2012087896A patent/SG186607A1/en unknown
- 2008-11-28 KR KR1020197011765A patent/KR20190045414A/ko not_active Ceased
- 2008-11-28 KR KR1020217012131A patent/KR20210049186A/ko not_active Ceased
- 2008-11-28 SG SG10201604258YA patent/SG10201604258YA/en unknown
- 2008-11-28 NZ NZ709704A patent/NZ709704A/en unknown
- 2008-11-28 NZ NZ622583A patent/NZ622583A/en unknown
- 2008-11-28 JP JP2010536208A patent/JP5840364B2/ja active Active
- 2008-11-28 KR KR1020107014593A patent/KR101868778B1/ko active Active
- 2008-11-28 KR KR1020157017584A patent/KR20150080038A/ko not_active Ceased
- 2008-11-28 AU AU2008334099A patent/AU2008334099B2/en active Active
- 2008-11-28 RU RU2010126658/15A patent/RU2473360C2/ru active
- 2008-11-28 CA CA2904458A patent/CA2904458C/en active Active
- 2008-11-28 TW TW102119838A patent/TWI629064B/zh not_active IP Right Cessation
- 2008-11-28 NZ NZ585702A patent/NZ585702A/xx not_active Application Discontinuation
- 2008-11-28 EP EP16200363.6A patent/EP3189831A1/en not_active Withdrawn
-
2010
- 2010-05-30 IL IL206081A patent/IL206081A/en active IP Right Grant
-
2012
- 2012-07-19 ZA ZA2012/05433A patent/ZA201205433B/en unknown
- 2012-11-06 RU RU2012147070A patent/RU2659431C2/ru active
-
2013
- 2013-12-09 IL IL229886A patent/IL229886B/en active IP Right Grant
-
2014
- 2014-04-01 JP JP2014075367A patent/JP2014159437A/ja active Pending
-
2015
- 2015-06-03 JP JP2015112856A patent/JP6752500B2/ja active Active
-
2016
- 2016-05-30 JP JP2016107020A patent/JP2016185971A/ja active Pending
-
2017
- 2017-12-21 IL IL256465A patent/IL256465B/en active IP Right Grant
-
2018
- 2018-01-23 JP JP2018008763A patent/JP2018080202A/ja active Pending
- 2018-10-08 IL IL262205A patent/IL262205A/en unknown
-
2020
- 2020-06-23 JP JP2020107507A patent/JP2020183387A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020183387A5 (2) | ||
| RU2008138646A (ru) | Жидкая композиция g-csf | |
| RU2019112680A (ru) | Жидкая фармацевтическая композиция | |
| JP2017516847A5 (2) | ||
| Ibañez et al. | M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A | |
| JP2013512889A5 (2) | ||
| RU2019116756A (ru) | Жидкая фармацевтическая композиция | |
| HRP20120893T1 (hr) | Formulacija protutijela na histidin-acetatnom puferu | |
| PE20230169A1 (es) | Suministro al sistema nervioso central de agentes terapeuticos | |
| HRP20181226T1 (hr) | Tekući farmaceutski sustav | |
| AR040881A1 (es) | Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-alfa | |
| JP2019509311A5 (2) | ||
| JP2013500947A5 (2) | ||
| HRP20160276T1 (hr) | Pripravci za imuniziranje protiv bakterije staphylococcus aureus | |
| EP0634937A1 (en) | Vaccines that contain non-ionic surfactant vesicles. | |
| RU2020117081A (ru) | Жидкие стабильные вакцины, содержащие вирус крупного рогатого скота | |
| JP2017516848A5 (2) | ||
| CN1842345A (zh) | 口服的固体剂型疫苗 | |
| US20210052725A1 (en) | Adjuvant system for oral vaccine administration | |
| RU2011122629A (ru) | Водная композиция, содержащая фолликулостимулирующий гормон | |
| JP2021521171A5 (2) | ||
| AR100268A1 (es) | Formulación líquida que comprende compuesto neutralizante de gm-csf | |
| RU2016105462A (ru) | Способы и композиции, которые обеспечивают модуляцию иммунных ответов, связанных с введением биофармацевтического лекарственного средства | |
| MX2021007393A (es) | Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf. | |
| RU2018129077A (ru) | Стабильная фармацевтическая композиция |